Jyong Biotech Ltd. Stock Price, News & Analysis

MENS Nasdaq

Welcome to our dedicated page for Jyong Biotech Ltd. news (Ticker: MENS), a resource for investors and traders seeking the latest updates and insights on Jyong Biotech Ltd. stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jyong Biotech Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jyong Biotech Ltd.'s position in the market.

06/18/2025 05:20 PM

News

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Rhea-AI Summary

Jyong Biotech Ltd. (NASDAQ: MENS), a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, has successfully completed its Initial Public Offering (IPO) on June 18, 2025. The company raised $20 million by offering 2,666,667 ordinary shares at $7.5 per share on the Nasdaq Global Market. The underwriters have a 45-day option to purchase up to 400,000 additional shares. The proceeds will be allocated to fund Phase III trials of MCS-2 (40%), earlier phase trials (25%), Phase II trial of PCP (10%), Phase I trial of IC (5%), and general corporate purposes (20%). Joseph Stone Capital, LLC served as the sole underwriter for this firm commitment offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Rhea-AI Summary

Jyong Biotech Ltd., a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, has announced the pricing of its IPO on the Nasdaq Global Market under the symbol MENS. The company is offering 2,666,667 ordinary shares at $7.50 per share, aiming to raise $20 million in gross proceeds. Trading will commence on June 17, 2025, with an additional over-allotment option of 400,000 shares. The proceeds will primarily fund Phase III trials of MCS-2 (40%), earlier phase trials (25%), Phase II trial of PCP (10%), Phase I trial of IC (5%), and general corporate purposes (20%). Joseph Stone Capital is serving as the sole underwriter for this firm commitment offering.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Jyong Biotech Ltd. (MENS)?

The current stock price of Jyong Biotech Ltd. (MENS) is $8 as of June 19, 2025.

Jyong Biotech Ltd.

Nasdaq:MENS

MENS Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

MENS Stock Data

Float 2.67M